Serum Immunoglobulin A Response to Human Papillomavirus Type 16 Virus-Like Particles in Human Immunodeficiency Virus (HFV)-Positive and High-Risk HIV-Negative Women

Journal of Infectious Diseases

Volumn 188, Issue 12, 2003, Pages 1834-1844

  Viscidi, Raphael P ^a,i   Ahdieh Grant, Linda ^b   Schneider, Michael F ^b   Clayman, Barbara ^a   Massad, L Stewart ^c   Anastos, Kathryn M ^d   Burk, Robert D ^e   Minkoff, Howard ^f   Palefsky, Joel ^g   Levine, Alexandra ^h   Strickler, Howard ^e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f MAIMONIDES MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SEXUAL BEHAVIOR; UTERINE CERVIX CYTOLOGY; VIRUS REPLICATION; WART VIRUS;

ANTIBODIES, VIRAL; CAPSID; CERVIX UTERI; COHORT STUDIES; CONFIDENCE INTERVALS; DNA, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; ODDS RATIO; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; UNITED STATES; VAGINA; VAGINAL SMEARS;

EID: 9144273194     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/379975     Document Type: Article

References (29)

1. Dillner J. The serological response to papillomaviruses. Semin Cancer Biol 1999; 9:423-30.
2. Conley ME, Delacroix DL. Intravascular and mucosal immunoglobulin A: two separate but related systems of immune defense? Ann Intern Med 1987; 106:892-9.
3. Welliver RC, Kaul TN, Putnam TI, et al. The antibody response to primary and secondary infection with respiratory syncytial virus: kinetics of class-specific responses. J Pediatr 1980; 96:808-13.
4. Salonen EM, Hovi T, Meurman O, Vesikari T, Vaheri A. Kinetics of specific IgA, IgD, IgE, IgG, and IgM antibody responses in rubella. J Med Virol 1985; 16:1-9.
5. Nikoskelainen J, Neel EU, Stevens DA. Epstein-Barr virus-specific serum immunoglobulin A as an acute-phase antibody in infectious mononucleosis. J Clin Microbiol 1979; 10:75-9.
6. Nielsen SL, Sorensen I, Andersen HK. Kinetics of specific immunoglobulins M, E, A, and G in congenital, primary, and secondary cytomegalovirus infection studied by antibody-capture enzyme-linked immunosorbent assay. J Clin Microbiol 1988; 26:654-61.
7. Rothbarth PH, Groen J, Bohnen AM, de Groot R, Osterhaus AD. Influenza virus serology - a comparative study. J Virol Methods 1999; 78:163-9.
8. Koraka P, Suharti C, Setiati TE, et al. Kinetics of dengue virus-specific serum immunoglobulin classes and subclasses correlate with clinical outcome of infection. J Clin Microbiol 2001; 39:4332-8.
9. Karner W, Bauer G. Activation of a varicella-zoster virus-specific IgA response during acute Epstein-Barr virus infection. J Med Virol 1994; 44:258-62.
10. Wittek AE, Arvin AM, Koropchak CM. Serum immunoglobulin A antibody to varicella-zoster virus in subjects with primary varicella and herpes zoster infections and in immune subjects. J Clin Microbiol 1983; 18:1146-9.
11. Madic J, Magdalena J, Quak J, van Oirschot JT. Isotype-specific antibody responses to bovine herpesvirus 1 in sera and mucosal secretions of calves after experimental reinfection and after reactivation. Vet Immunol Immunopathol 1995; 47:81-92.
12. Henle G, Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 1976; 17:1-7.
13. Chien YC, Chen JY, Liu M, et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med 2001; 345:1877-82.
14. Petter A, Heim K, Guger M, et al. Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women. J Gen Virol 2000; 81:701-8.
15. Wang Z-H, Kjellberg L, Abdalla H, et al. Type specificity and significance of different isotypes of serum antibodies to human papillomavirus capsids. J Infect Dis 2000; 181:456-62.
16. Sasagawa T, Yamazaki H, Dong YZ, et al. Immunoglobulin-A and -G responses against virus-like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intra-epithelial lesions. Int J Cancer 1998; 75:529-35.
17. Bontkes HJ, de Gruijl TD, Walboomers JM, et al. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16. J Gen Virol 1999; 80:409-17.
18. Marais DJ, Vardas E, Ramjee G, et al. The impact of human immunodeficiency virus type 1 status on human papillomavirus (HPV) prevalence and HPV antibodies in serum and cervical secretions. J Infect Dis 2000; 182:1239-42.
19. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology 1998; 9:117-25.
20. Viscidi RP, Ahdieh-Grant L, Clayman B, et al. Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women. J Infect Dis 2003; 187:194-205.
21. Palefsky JM, Minkoff H, Kalish LA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999; 91: 226-36.
22. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA 1994; 271:1866-9.
23. Studentsov YY, Schiffman M, Strickler HD, et al. Enhanced enzyme-linked immunosorbent assay for detection of antibodies to virus-like particles of human papillomavirus. J Clin Microbiol 2002; 40:1755-60.
24. Herrero R, Schiffman MH, Bratti C, et al. Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev Panam Salud Publica 1997; 1:362-75.
25. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42:121-30.
26. Janeway CA, Travers P, Walport M, Shlomchik MJ. Structual variation in immunoglobulin constant regions. In: Janeway CA, Travers P, Walport M, Shlomchik MJ, eds. Immunobiology: the immune system in health and disease. 5th ed. New York: Garland Publishing, 2001:141-51.
27. Strickler HD, Schiffman MH, Eklund C, et al. Evidence for at least two distinct groups of humoral immune reactions to papillomavirus antigens in women with squamous intraepithelial lesions. Cancer Epidemiol Biomarkers Prev 1997; 6:183-8.
28. Strickler HD, Palefsky JM, Shah KV, et al. Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst 2003; 95:1062-71.
29. Ho GYF, Studentsov Y, Hall CB, et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 2002; 186:737-42.